Abstract 4142996: Controlled LDL levels can Attenuate the Lp(a) Cardiovascular Risk in Patients Who Underwent Percutaneous Coronary Intervention
Background: Secondary prevention after percutaneous coronary interventions (PCIs) is still challenging and lipoprotein(a) [Lp(a)] is believed to be a residual risk factor in this setting. However, the effect of Lp(a) in case of well-controlled low-density lipoprotein cholesterol (LDL-C) is still unclear. The interaction between Lp(a) and LDL-C has been studied in primary prevention but still needs to be investigated in secondary prevention. Hypothesis: Achieving adequate LDL-C control after PCI may reduce the cardiovascular (CV) risk associated with Lp(a). Methods: A retrospective study of consecutive patients who underwent PCI and reached their LDL-C target levels (<70mg/dL) at three academic centers sites between 2006 and 2017. All included patients must have an Lp(a) measurement before the PCI intervention. Clinical outcomes on 10-year follow-up were collected by reviewing the electronic patients' records. The primary outcomes included all-cause mortality (ACM) and major adverse CV events (MACE) including non-fatal MI, ischemic stroke, coronary revascularization, and CV death. Kaplan-Meier curves were created to compare the survival probabilities among patients with high Lp(a) (≥50mg/dL) versus those with low Lp(a) (<50mg/dL). Univariate and multivariate Cox regression analyses were performed to quantify the association of elevated Lp(a) with outcomes and control for potential confounders. Results: In total, 878 patients (median age = 68 years, 74% males) were included in the analysis. Of them, 242 (27.6%) had high Lp(a) ≥50mg/dL. Kaplan Meier analyses did not reveal any significant difference in survival probabilities across the Lp(a) groups for any of the outcomes (Figure 1). The results were consistent in univariate (MACE, HR: 1.08 [95%CIs 0.85-1.35]; ACM, HR: 0.97 [95% CI 0.76-1.23]) and multivariate analyses (MACE, HR: 1.14, [95% CIs 0.90-1.45]; ACM, HR: 1.08 [95% CI 0.84-1.39]). Conclusion: These findings suggest that, in patients who underwent PCI and achieved an LDL-C target of <70 mg/dL, elevated Lp(a) levels were not associated with and increased risk of MACE or mortality. Controlling the LDL-C should still be the cornerstone in secondary prevention after PCI, however, larger prospective studies are still warranted to validate our results.
Authors
- Milagros Pereyra (ORCID: https://orcid.org/0000-0003-4695-8436)
- Chadi Ayoub (ORCID: https://orcid.org/0000-0001-5877-7478)
- Isabel G. Scalia (ORCID: https://orcid.org/0000-0002-6459-9767)
- Ahmed Mahmoud (ORCID: https://orcid.org/0009-0009-9729-9961)
- Nobuhisa Baba
- Kamal Awad (ORCID: https://orcid.org/0000-0001-6707-1629)
- Juan Farina (ORCID: https://orcid.org/0000-0002-5824-8485)
- Amro Badr (ORCID: https://orcid.org/0000-0003-0107-1436)
- Mohammed Tiseer Abbas
- Hesham Abdalla
- Moaz Kamel
- Mohammed M. Elahi
- Reza Arsanjani
Institutions
- Mayo Clinic in Arizona (US)
- Mayo Clinic Hospital (US)
Publication Details
- Journal
- Circulation
- Published
- 2024-11-12
- DOI
- https://doi.org/10.1161/circ.150.suppl_1.4142996
- Primary Topic
- Lipoproteins and Cardiovascular Health
- Type
- article
- Field-Weighted Citation Impact
- 0.00